Tags

Type your tag names separated by a space and hit enter

[Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
Ned Tijdschr Geneeskd. 1999 Aug 28; 143(35):1777-80.NT

Abstract

OBJECTIVE

To evaluate costs and benefits of the screening and immunisation policy for hepatitis A virus (HAV) infection among travellers from Rotterdam.

DESIGN

Descriptive and cost-benefit analysis.

METHOD

From the data of the Municipal Health Service Rotterdam (GGD), the Netherlands, the details were collected on individuals travelling frequently to HAV endemic countries, who were born before 1950, or had lived for more than 10 years in an HAV endemic country or had ever suffered jaundice. Persons to whom these criteria applied were screened for HAV antibodies at the GGD before immunisation for HAV in the period January 1st 1996-June 30th 1998. Screening and vaccination policies were compared with a cost analysis.

RESULTS

Antibodies against HAV were found in 79% of 1466 screened people. The lowest prevalence of antibodies was found among Dutch nationals (67%). A significantly higher prevalence was found amongst individuals from Turkey/Morocco (96%) and from the Cape-Verde Islands (97%). In the cost analysis the break even point, the prevalence level of HAV antibodies in the population at which screening cost as much as blind prophylaxis, lay for passive immunisation between 69% and 93%. For active immunisation this point lay around 17%.

CONCLUSION

The selection criteria for prevaccination screening are effective in identifying individuals with a high probability of being immune against HAV infections. The current screening policy for antibodies against HAV is cost effective.

Authors+Show Affiliations

Afd. Algemene Infectieziekten, Gemeentelijke Gezondheidsdienst voor Rotterdam en Omstreken. reintjes@as-ms.loegd.mhs.nrw.deNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

10494329

Citation

Reintjes, R, et al. "[Screening Policy for Travellers From Rotterdam for Hepatitis a Antibodies Prior to Eventual Immunization: Favourable Cost-benefit Ratio]." Nederlands Tijdschrift Voor Geneeskunde, vol. 143, no. 35, 1999, pp. 1777-80.
Reintjes R, Bosman A, de Zwart O. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio]. Ned Tijdschr Geneeskd. 1999;143(35):1777-80.
Reintjes, R., Bosman, A., & de Zwart, O. (1999). [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio]. Nederlands Tijdschrift Voor Geneeskunde, 143(35), 1777-80.
Reintjes R, Bosman A, de Zwart O. [Screening Policy for Travellers From Rotterdam for Hepatitis a Antibodies Prior to Eventual Immunization: Favourable Cost-benefit Ratio]. Ned Tijdschr Geneeskd. 1999 Aug 28;143(35):1777-80. PubMed PMID: 10494329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio]. AU - Reintjes,R, AU - Bosman,A, AU - de Zwart,O, PY - 1999/9/24/pubmed PY - 1999/9/24/medline PY - 1999/9/24/entrez SP - 1777 EP - 80 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 143 IS - 35 N2 - OBJECTIVE: To evaluate costs and benefits of the screening and immunisation policy for hepatitis A virus (HAV) infection among travellers from Rotterdam. DESIGN: Descriptive and cost-benefit analysis. METHOD: From the data of the Municipal Health Service Rotterdam (GGD), the Netherlands, the details were collected on individuals travelling frequently to HAV endemic countries, who were born before 1950, or had lived for more than 10 years in an HAV endemic country or had ever suffered jaundice. Persons to whom these criteria applied were screened for HAV antibodies at the GGD before immunisation for HAV in the period January 1st 1996-June 30th 1998. Screening and vaccination policies were compared with a cost analysis. RESULTS: Antibodies against HAV were found in 79% of 1466 screened people. The lowest prevalence of antibodies was found among Dutch nationals (67%). A significantly higher prevalence was found amongst individuals from Turkey/Morocco (96%) and from the Cape-Verde Islands (97%). In the cost analysis the break even point, the prevalence level of HAV antibodies in the population at which screening cost as much as blind prophylaxis, lay for passive immunisation between 69% and 93%. For active immunisation this point lay around 17%. CONCLUSION: The selection criteria for prevaccination screening are effective in identifying individuals with a high probability of being immune against HAV infections. The current screening policy for antibodies against HAV is cost effective. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/10494329/[Screening_policy_for_travellers_from_Rotterdam_for_hepatitis_A_antibodies_prior_to_eventual_immunization:_favourable_cost_benefit_ratio]_ DB - PRIME DP - Unbound Medicine ER -